Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
| Status: | Recruiting |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 2/8/2015 |
| Start Date: | January 2013 |
| Contact: | Emal contact via H.Lundbeck A/S |
| Email: | LundbeckClinicalTrials@Lundbeck.com |
Interventional, Randomised, Double-blind, Placebo-controlled, Sequential Group, Multiple Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF35700 in Patients With Schizophrenia
The purpose of this study is to evaluate the tolerability and safety of Lu AF35700 after
repeated oral dosing to patients with schizophrenia.
repeated oral dosing to patients with schizophrenia.
Inclusion Criteria:
- Men or women between 18 and 60 years (extremes included)
- BMI of ≤38
- Primary diagnosis of schizophrenia according to DSM-IV-TR™ (codes 295.10, 295.20,
295.30, 295.90)
- Clinical Global Impression - Severity of Illness (CGI-S) score ≤4 (moderately ill) at
screening and baseline
- PANSS total score ≤80
- Score ≤4 (moderate) on the following PANSS items at screening and safety baseline: P7
(hostility), G8 (uncooperativeness)
- Willing to be hospitalised for 4 to 5 weeks after the Safety Baseline Visit
Exclusion Criteria:
- The patient experienced an acute exacerbation requiring hospitalization within the
last 6 months
- The patient experienced an acute exacerbation requiring change in antipsychotic
medication (with reference to drug or dose) within the last 4 weeks
- The patient has a diagnosis or history of substance dependence (except nicotine) or
substance abuse according to DSM-IV-TR® criteria ≤3 months prior to screening
- The patient smokes >20 cigarettes per day
Other protocol-defined inclusion and exclusion criteria may apply
We found this trial at
1
site
Click here to add this to my saved trials
